OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryGlobe Newswire • 23 days ago
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Share to Feed
OKYO Pharma Limited (NASDAQ:OKYO - Get Free Report) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 50,800 shares, a drop of 21.4% from the...
Ocular Pain Relief showed statistically significant improvement as early as day 15 and the benefit was durable throughout the trial.Conjunctival Staining improved as early as day 29 with a durable...
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Limited (NASDAQ:OKYO Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 29th, there was short interest...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needThe...
OKYO Pharma gains on receiving FDA nod of IND for OK-101 in neuropathic corneal pain...
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...